financetom
Business
financetom
/
Business
/
Trump presses advisers for tariff escalation ahead of April 2, Washington Post reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trump presses advisers for tariff escalation ahead of April 2, Washington Post reports
Mar 29, 2025 5:30 AM

(Reuters) - U.S. President Donald Trump is urging senior advisers to take a more aggressive stance on tariffs as the administration prepares for a major escalation in its global trade war, the Washington Post reported on Saturday, citing four people familiar with the matter.

Despite calls from allies on Wall Street and Capitol Hill to adopt a more measured approach, Trump has been pushing for sweeping trade actions aimed at reshaping the U.S. economy, the report said.

Trump has continued to tell his advisers that he wants to keep increasing trade measures, and in recent days, he has brought back the idea of a universal tariff that would apply to most imports, no matter which country they come from, according to the report.

The White House did not immediately respond to a request for comment.

Trump has expressed regret over not implementing broader tariffs during his first term and has blamed advisers for persuading him to pull back, the Post said, adding it remains unclear how seriously the idea of a universal tariff is being considered.

The president has told advisers that tariffs are a win for the United States, bringing back manufacturing jobs and adding trillions in government revenue, according to the Post.

Earlier on Friday, Trump said that he was open to carving out deals with countries seeking to avoid U.S. tariffs but those agreements would have to be negotiated after his administration announces reciprocal levies on April 2.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UiPath 'Executing Well' in Tough Environment, Oppenheimer Says
UiPath 'Executing Well' in Tough Environment, Oppenheimer Says
Sep 5, 2025
11:02 AM EDT, 09/05/2025 (MT Newswires) -- UiPath ( PATH ) is executing well in a challenging operating environment, with an improving sales performance and a net retention rate expected to stabilize in fiscal H2, Oppenheimer said Friday in a report. Management raised fiscal 2026 targets above the fiscal Q2 upside, signaling strengthening business trends, the report said. On Thursday,...
Aldebaran to Spin Out Argentina Exploration Projects Into New Subsidiary
Aldebaran to Spin Out Argentina Exploration Projects Into New Subsidiary
Sep 5, 2025
11:03 AM EDT, 09/05/2025 (MT Newswires) -- Aldebaran Resources ( ADBRF ) said Friday it will transfer its projects in Salta, Jujuy and Catamarca provinces of Argentina into a new Canadian subsidiary, while focusing on its Altar copper-gold project in San Juan. The subsidiary will be led by Sam Leung as chief executive. Leung has served as a director of...
Carney, Canadian actors honor hometown comedy legend John Candy at TIFF
Carney, Canadian actors honor hometown comedy legend John Candy at TIFF
Sep 5, 2025
TORONTO, Sept 5 (Reuters) - At a time of heightened patriotism in Canada, the Toronto International Film Festival kicked off its 50th edition with a documentary honoring Canadian comedian John Candy. The world premiere of John Candy: I Like Me on Thursday evening had the audience, including Prime Minister Mark Carney, rolling with laughter remembering the comedy legend's classic characters...
United Therapeutics' Tyvaso Win in IPF Clears Path for More Revenue, Oppenheimer Says
United Therapeutics' Tyvaso Win in IPF Clears Path for More Revenue, Oppenheimer Says
Sep 5, 2025
11:07 AM EDT, 09/05/2025 (MT Newswires) -- United Therapeutics ( UTHR ) has a clear path for additional revenue of $5.4 billion from Tyvaso by 2033 following positive results in a clinical trial for idiopathic pulmonary fibrosis, Oppenheimer said in a note Friday. The trial results were in-line with Oppenheimer's base case scenario of Tyvaso reaching statistically significant benefit in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved